












## S1: Individual profiles of 61 incident cases




A. Incident cases for HerpeSelect (IV>1.10) and Kalon assays (IV>1.10) using manufacturer's cut-off (n = 35)















B. Additional incident cases with HerpeSelect ( $IV > 1.10$ ) and Kalon assays using lowered cut-off ( $IV > 0.66$ )  
 (n = 9)







C. Incident cases only with HerpeSelect assay ( $IV > 1.10$ ) ( $n=7$ )





D. Cases that were found to be not HSV-2 sero-negative at baseline using HerpeSelect (IV>1.10) and Kalon using lowered cut off (IV>0.66) (n = 7)





E. Cases that were found to be not HSV-2 sero-negative at baseline using only HerpeSelect (IV>1.10) (n=3)

